Department of Medical Pathology and Post Graduation Program in Obstetrics and Gynecology Professor, Clinical Hospital, Federal University of Paraná, Curitiba, Paraná, Brazil
Research Article
Comparison between Ki67 Expression and Oncotype Dx® Recurrence Score in Luminal Breast Carcinomas
Author(s): Ana Helena Willrich Rasera*, Cleverton Spautz, Iris Rabinovich, Ana Cléa Andrade, Cícero Urban, Karina Furlan Anselmi and Ana Paula Martins Sebastião
Introduction: In early-stage breast cancer, there is a constant search to identify which patients will benefit from chemotherapy. Among the most widely used genetic tests is Oncotype DX®, a validated prognostic marker. However, its high cost is still a major limitation. As a more financially viable alternative, the cell proliferation index determined by the Ki67 antigen is used. Objective: To evaluate the percentage of Ki67 expression and its relationship with the Oncotype DX® recurrence score in luminal breast carcinomas.
Methods: 79 Oncotype DX® results available in the last 5 years were analyzed and compared with the respective anatomopathological and immunohistochemical reports.
Results: The mean age was 56 years with tumors ≤ 2 cm (72.2%), with a predominance of carcinomas of no special type (73.. Read More»
Cancer Science & Therapy received 5332 citations as per Google Scholar report